Rodney has made over 5 trades of the Zomedica Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 26,900 units of ZOM stock worth $32,280 on 20 December 2018.
The largest trade he's ever made was exercising 140,000 units of Zomedica Pharmaceuticals stock on 23 March 2018 worth over $28,000. On average, Rodney trades about 21,488 units every 34 days since 2018. As of 20 December 2018 he still owns at least 161,900 units of Zomedica Pharmaceuticals stock.
You can see the complete history of Mr. Williams stock trades at the bottom of the page.
Rodney J. Williams is Independent Member of the Company. He has over 20 years of medical technology and related healthcare experience, Rodney “Rod” Williams successfully guided both large and small cap companies through growth cycles, while strengthening product portfolios and boosting commercial planning competencies. He is an entrepreneur-in- residence with PTV Healthcare Capital, a private equity investment firm known for transforming early and middle-market companies into efficient and diversified businesses with superior growth profiles. Rod is the former President and CEO of Heart Rhythm Society Consulting Services where he established specific business services to improve the operating performance and profitability of hospitals, integrated delivery networks, and cardiology practices. He also served in senior executive positions with St. Jude Medical, GE Healthcare, Johnson and Johnson, and Bausch & Lomb. Rod earned his MBA and Bachelor of Science degree from the University of Southern California and attended the General Management Executive Leadership Program at The Wharton School of Business.
Rodney's mailing address filed with the SEC is C/O ZOMEDICA CORP., 100 PHOENIX DRIVE,, SUITE 125, ANN ARBOR, MI, 48108.
Over the last 5 years, insiders at Zomedica Pharmaceuticals have traded over $7,040 worth of Zomedica Pharmaceuticals stock and bought 3,375,000 units worth $601,250 . The most active insiders traders include Robert Cohen, Johnny D Powers und Stephanie Morley. On average, Zomedica Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $39,452. The most recent stock trade was executed by Larry C Ii Heaton on 5 September 2024, trading 100,000 units of ZOM stock currently worth $13,000.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Zomedica Pharmaceuticals executives and other stock owners filed with the SEC include: